Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.80 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.80 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.80 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.80 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.80 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylmorphine SCHEMBL14516212 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL18770594 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL15757784 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL14611951 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL29392212 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL15653227 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL16922138 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL220710 | 0.99 | OPRD1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL29845657 | 0.98 | OPRM1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL17747970 | 0.98 | OPRM1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9976 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| EP-0214735-B1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION | Euroceltique S.A. (LU) | 1991-08-28 | — | — | EP | claimed |
| WO-1990013634-A2 | ENZYMES AND THEIR USE IN DRUG DETECTION | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-11-15 | — | — | WO | claimed |
| EP-0220805-B1 | MULTIPHASE TABLET AND PROCESS FOR THE PREPARATION THEREOF | Euroceltique S.A. (LU) | 1989-09-20 | — | — | EP | claimed |
| US-4844907-A | COMBINATION OF NARCOTIC AND NON-STEROIDAL ANTI-INFLAMMATORY | EUROCELTIQUE, S.A. (LU) | 1989-07-04 | — | — | US | claimed |
| US-4834965-A | Controlled release pharmaceutical composition | EUROCELTIQUE, S.A. (LU) | 1989-05-30 | — | — | US | claimed |
| EP-0192909-B1 | PROCESS FOR OBTAINING PHARMACEUTICAL FORMS WITH SUSTAINED RELEASE | CORTIAL S.A. (FR) | 1989-05-10 | — | — | EP | claimed |
| EP-0220805-A2 | Multiphase tablet and process for the preparation thereof | Euroceltique S.A. (LU) | 1987-05-06 | — | — | EP | claimed |
| EP-0214735-A1 | Controlled release pharmaceutical composition | Euroceltique S.A. (LU) | 1987-03-18 | — | — | EP | claimed |
| US-4401672-A | Non-addictive narcotic antitussive preparation | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1983-08-30 | — | — | US | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |